Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of diabetes
3.2.1.2 High preference for biguanides as first line treatment
3.2.1.3 Advancements in drug delivery technologies
3.2.2 Industry pitfalls & challenges
3.2.2.1 Side effects associated with biguanides
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.5.1 Supplier power
3.5.2 Buyer power
3.5.3 Threat of new entrants
3.5.4 Threat of substitutes
3.5.5 Industry rivalry
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Branded
5.3 Generic
Chapter 6 Market Estimates and Forecast, By Dosage Form, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Tablets
6.3 Oral solutions
Chapter 7 Market Estimates and Forecast, By Formulation, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Immediate-release
7.3 Extended-release
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Boehringer Ingelheim International GmbH
10.2 Bristol-Myers Squibb Company
10.3 Cipla Ltd.
10.4 GlaxoSmithKline plc
10.5 Glenmark Pharmaceuticals Ltd.
10.6 Merck & Co., Inc.
10.7 Sanofi
10.8 Takeda Pharmaceutical Company Limited.
10.9 Teva Pharmaceuticals Industries Ltd.
10.10 Zydus Group
